Greenlight Biosciences (ENVI) Adds Two World-Renowned Scientists To Its Scientific Advisory Board
GreenLight Biosciences has appointed Professor Diane E. Griffin and Emmanuel Hanon to its Human Health Scientific Advisory Board. Professor Griffin, a distinguished figure in medicine and immunology, brings extensive expertise in RNA virus infections, while Dr. Hanon, with a rich background in vaccine R&D at GlaxoSmithKline, will bolster the company's development efforts. This strategic move aims to enhance GreenLight's capabilities in mRNA vaccines and therapeutics, pivotal for addressing global health challenges. The company is also preparing for a public listing through Environmental Impact Acquisition Corp. (NASDAQ: ENVI).
- Appointment of experts enhances R&D capabilities for RNA-based solutions.
- Diane Griffin's expertise in virology supports vaccine development.
- Emmanuel Hanon's experience accelerates product development in vaccines.
- Dependence on new advisory board members may pose continuity risks.
- Potential delays in public listing could impact stock performance.
BOSTON, Nov. 4, 2021 /PRNewswire/ -- GreenLight Biosciences is delighted to announce the appointment of Professor Diane E. Griffin, MD, PhD, and Emmanuel Hanon, DVM, PhD, to its Human Health Scientific Advisory Board.
At Johns Hopkins University, Diane Griffin is the Distinguished Service Professor, a professor of Medicine and Neurology at the School of Medicine, and the W. Harry Feinstone professor at the Department of Molecular Microbiology and Immunology at the Bloomberg School of Public Health. She has also been vice president of the U.S. National Academy of Sciences since 2013. Professor Griffin brings the experience of a distinguished career to facilitate the R&D work of GreenLight, especially her focus on pathogenesis of acute RNA virus infections and the role of the immune response in virus clearance, protection from infection, and mechanisms of vaccine-induced protection.
Emmanuel Hanon's 20-year career at GlaxoSmithKline included 7 years as the GSK Vaccines' senior vice president and head of R&D. As a virologist and immunologist, he made critical contributions to next-generation adjuvants and their inclusion in successful vaccines for pandemic influenza, malaria, and shingles. He currently serves as head of R&D for Viome, a precision medicine company focusing on chronic disorders. Dr. Hanon's experience in vaccinology and product development will be critical in helping GreenLight accelerate its development programs.
Amin Khan, GreenLight's Human Health chief scientific officer, said: "GreenLight aims to solve some of the world's biggest problems by delivering on the full potential of RNA, including producing vaccines and gene therapies. We're delighted that Diane and Emmanuel have joined our Scientific Advisory Board. Their expertise in virology, immunology, public health, and product development will help us accelerate our progress."
About GreenLight Biosciences, Inc.
Founded in 2008, GreenLight's aims to solve some of the world's biggest problems by delivering on the full potential of RNA for human health and agriculture.
In human health, this includes mRNA vaccines and therapeutics. In agriculture, this includes RNA to protect honeybees and a range of crops. The company's breakthrough cell-free RNA manufacturing platform, which is protected by numerous patents, allows for cost-effective and scalable production of RNA. For more information, visit https://www.greenlightbiosciences.com/
In August 2021, GreenLight Biosciences announced plans to become publicly listed through a business combination with Environmental Impact Acquisition Corp. (NASDAQ: ENVI).
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, with respect to the proposed transaction between GreenLight Biosciences, Inc. ("GreenLight") and Environmental Impact Acquisition Corp. ("ENVI"). These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result" and similar expressions. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect the price of ENVI's securities and the effect of the announcement or pendency of the transaction on GreenLight's business relationships, operating results, and business generally. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and ENVI and GreenLight assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
View original content to download multimedia:https://www.prnewswire.com/news-releases/greenlight-biosciences-envi-adds-two-world-renowned-scientists-to-its-scientific-advisory-board-301416685.html
SOURCE GreenLight Biosciences, Inc.
FAQ
What is the significance of Diane Griffin's appointment to GreenLight Biosciences?
How does Emmanuel Hanon's experience benefit GreenLight Biosciences?
What is the relationship between GreenLight Biosciences and Environmental Impact Acquisition Corp. (ENVI)?
What challenges could arise from the new appointments at GreenLight Biosciences?
